vimarsana.com

Page 27 - லிநேபேர்கேற் விரிவான புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tracking a virus villain | UNC-Chapel Hill

COVID-19 is a tricky, slippery villain. Sometimes it looks like a bad cold or the flu; at other times, a heart attack or stroke. All over the world, it eludes the heroes in the white coats by changing its identity, location by location. Clearly, this viral villain requires vigilant surveillance. And the implementation of “alternative COVID-19 surveillance methods” is just what the North Carolina General Assembly singled out when it allocated $15 million of the latest federal COVID-19 funding to the North Carolina Policy Collaboratory based at Carolina. The $15 million allocation approved by the state legislature in March is subject to Centers for Disease Control and Prevention approval since the funding is allocated by the CDC Epidemiology and Laboratory Capacity cooperative funding agreement to the North Carolina Department of Health and Human Services to detect, respond to, control and prevent infectious diseases.

Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors

Share this article SAN DIEGO and CALGARY, AB, April 5, 2021 /CNW/ Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, the immunotherapeutic effects of pelareorep in breast cancer, and its synergistic activity with CAR T cells in solid tumors. The webinar will take place on Monday, April 12, 2021 at 2:00 pm ET. The webinar will feature presentations by Key Opinion Leaders Aleix Prat, M.D., Ph.D. (Clínic Barcelona) and Richard Vile, Ph.D., (Mayo Clinic). Dr. Prat s portion of the presentation will focus on data from the AWARE-1 window-of-opportunity clinical trial evaluating pelareorep with and without atezolizumab (Tecentriq

Oncolytics Biotech to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors

Oncolytics Biotech to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.